Glofitamab
Glofitamab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Non-Hodgkin Lymphoma, B-cell、B Cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
1 项
已进入 III/IV 期
21 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Ryvu Therapeutics SA
- M.D. Anderson Cancer Center
- Hoffmann-La Roche
- Peking University Third Hospital
- National Research Center for Hematology, Russia
- BeOne Medicines
- Institute of Hematology & Blood Diseases Hospital, China
- The First Affiliated Hospital of Xiamen University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、澳大利亚、加拿大、法国、德国、意大利、South Korea、Brazil、中国、Czechia、丹麦、Hungary
正在招募患者的 Glofitamab 研究
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
II 期招募中美国澳大利亚加拿大法国NCT06806033A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
I 期 / II 期招募中美国澳大利亚Brazil中国NCT05533775Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
II 期招募中中国NCT07460362A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
III 期招募中美国澳大利亚Brazil加拿大NCT06084936Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas
II 期招募中RussiaNCT07883135A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
I 期 / II 期招募中美国澳大利亚Brazil中国NCT06634589Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
II 期招募中中国NCT06996132Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
II 期招募中中国NCT07749365MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
II 期招募中法国Poland西班牙英国NCT06534437A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
II 期招募中美国NCT05800366Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
II 期招募中中国NCT06570447A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
II 期招募中英国NCT06071871Glofitamab in Real Life
不适用招募中法国NCT06994169Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
II 期招募中美国NCT06054776Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
II 期招募中LebanonNCT07387848Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
II 期招募中美国NCT06043674Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
II 期招募中加拿大NCT06050694AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
I 期招募中美国NCT07649304A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
II 期招募中美国NCT06213311The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
II 期招募中中国NCT07240194Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
I 期 / II 期招募中美国NCT05861050Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
II 期招募中中国NCT06682130A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
II 期招募中澳大利亚NCT05833763External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
I 期招募中美国NCT07528352
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。